Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 7, Issue 6, 2005, Pages 633-641

  Strowig, Suzanne M ^a   Raskin, Philip ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Insulin; Metformin; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ANEMIA; BODY WEIGHT DISORDER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL TOXICITY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIVER CELL DAMAGE; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 27744552694     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00440.x     Document Type: Review

References (85)

1. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in The United States. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2003.
2. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78: 809A-809F.
3. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989; 262: 2708-2713.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
6. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1998; 37: 1595-1607.
7. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998; 21: 1138-1145.
8. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999; 58 (Suppl. 1): 31-39 [Review].
9. Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999; 20: 489-503 [Review].
10. DeFronzo RA, Goodman AM. The Multicenter Metformin Study Group, efficacy of metformin in patients with non-insulin dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
11. Fontbonne A, Charles MA, Juhan-Vague I et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group. Diabetes Care 1996; 19: 920-926.
12. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-1669.
13. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192 [Review].
14. Scheen AJ, Lefèbvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22: 1568-1577.
15. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-873.
16. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530-537.
17. Finegood DT, McArthur MD, Kojwang D et al. β cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
18. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21: 796-799.
19. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW (The Troglitazone Study Group). Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 1998; 83: 3169-3176.
20. Kobayashi J, Nagashima I, Hikita M et al. Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 1999; 47: 433-439.
21. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316-320.
22. Sung BH, Izzo JL, Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999; 34: 83-88.
23. Osanai H, Toki Y, Nakashima Y, Okumura K, Ito T, Hayakawa T. Reduction of vascular tone by introduction of troglitazone to the canine coronary artery. Arzneimittel-Forschung 1999; 49: 26-29.
24. Fujishima S, Ohya Y, Nakamura Y, Onaka U, Abe I, Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens 1998; 11: 1134-1137.
25. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-639.
26. Kotchen TA, Zhang HY, Reddy S, Hoffman RG. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 1996; 270 (Suppl. 3, Pt 2): R660-R666.
27. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24: 392-397.
28. Collins AR, Meehan WP, Kintscher U et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365-371.
29. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820.
30. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
31. Garvey WT, Olefsky JM, Griffin J. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222-234.
32. Firth RG, Bell PM, Rizza RA. Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1986; 314: 1280-1286.
33. Samanta A, Burden AC, Kinghorn HA. A comparative study of sulphonylurea and insulin therapy in non-insulin dependent diabetics who had failed on diet therapy alone. Diabetes Res 1987; 4: 183-185.
34. Kudlacek S, Schernthaner G. The effect of insulin treatment on HbAlc, body weight, and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. Horm Metab Res 1992; 24: 478-483.
35. Groop L, Widen E, Franssila-Kallunki A et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 599-605.
36. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type 2 diabetes. Application, benefits, and risks. Diabetes Rev 1995; 3: 308-334.
37. Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism 1996; 45: 1508-1513.
38. Sinha A, Formica C, Tsalamandris C et al. Effect of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabet Med 1996; 13: 40-46.
39. Lindstrom T, Eriksson P, Olsson AG, Arnqvist HJ. Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure. Diabetes Care 1994; 17: 719-721.
40. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002; 25: 1691-1698.
41. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-month outpatient trial. Diabetes Care 1993; 16: 21-31.
42. The DCCT Research Group. The relationship of glycemic exposure (HbAlc) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
43. Turner RC, Cull CA, Frighi V, Holman RR [UK Prospective Diabetes Study. (UKPDS) Group]. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
44. Turner RC. The U.K. Prospective Diabetes Study: a review. Diabetes Care 1998; 21 (Suppl. 3): C35-C38.
45. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408.
46. Wulffelé MG, Kooy A, Lehert P et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-2140.
47. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182-188.
48. Fritsche A, Schmülling R-M, Häring H-U, Stumvoll M. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol 2000; 37: 13-18.
49. Ponssen HH, Elte JWF, Lehert P, Schouten JP, Bets D. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 709-718.
50. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998; 21: 701-705.
51. Hermann LS, Kalén J, Katzman P et al. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 2001; 3: 428-434.
52. Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial. Diabet Med 1998; 15: 997-1002.
53. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
54. Borst SE, Snellen HG, Lai HL. Metformin treatment enhances insulin-stimulated glucose transport in skeletal muscle of Sprague-Dawley rats. Life Sci 2000; 67: 165-174.
55. Meyer L, Bohme P, Delbachian I et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002; 25: 2153-2158.
56. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled dose-response trial. Am J Med 1997; 103: 491-497.
57. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265-266.
58. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-917 [Comment].
59. Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 1080.
60. Neuschwander-Tetri BA, Isley WL, Oki JC et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 1998; 129: 38-41.
61. Murphy EJ, Davern TJ, Shakil AO et al. Troglitazone-induced fulminant hepatic failure: Acute Liver Failure Study Group. Dig Dis Sci 2000; 45: 549-553.
62. Salzman A, Patel J. Rosiglitazone therapy is not associated with hepatotoxicity. Diabetes 1999; 48 (Suppl. 1): A95.
63. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132: 118-121.
64. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone; a case report. Ann Intern Med 2000; 132: 121-124.
65. Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure. Ann Intern Med 2000; 132: 164 [Letter].
66. Schwartz S, Raskin P, Fonseca V, Graveline JF for the Troglitazone and Exogenous Insulin Study Group. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998; 338: 861-866.
67. Fonseca V, Foyt HL, Shen K, Whitcomb R. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients. Diabetes Care 2000; 23: 354-359.
68. Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. Diabetes Care 1998; 21: 1455-1461.
69. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J for the Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232.
70. Buch HN, Baskar V, Barton DM, Kamalakannan D, Akarca C, Singh BM. Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diabet Med 2002; 19: 572-574.
71. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S (Pioglitazone 014 Study Group). Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257.
72. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999; 48: 2414-2421.
73. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
74. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303 [Review].
75. Yale JF, Valiquett, TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL for the Troglitazone Triple-Therapy Study Group. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 737-745.
76. Dailey GE, Noor MA, Park J-S, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004; 116: 223-229.
77. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003; 26: 3273-3279.
78. Strowig SM, Avilés-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 2004; 27: 1577-1583.
79. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance. Diabetes Care 2003; 26: 138-143.
80. Särnblad S, Kroon M, Åman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomized placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003; 149: 323-329.
81. Strowig SM, Rakin P. The effect of rosiglitazone in overweight type 1 diabetes mellitus. Diabetes 2004; 53: A147.
82. Reynolds LR, Konz EC, Frederich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention in long-standing type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 270-275.
83. Asnani S, Richard BC, Desouza C, Fonseca V. Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin 2003; 19: 609-613.
84. American Diabetes Association. Position statement: hypertension management in adults with diabetes. Diabetes Care 2004; 27: S65-S67.
85. American Diabetes Association Position Statement. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27: S68-S71.